Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
179 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 24, 2023
1/24/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 44,300 shares of the Company’s common stock at an exercise price per share of $22.02, which was the closing price on January 23, 2023, and restricted stock units to acquire a total of 22,150 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - January 10, 2023
1/10/2023
Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s common stock at an exercise price per share of $17.51, which was the closing price on January 9, 2023.
-
Arcus Biosciences Announces New Employment Inducement Grants - December 24, 2022
12/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted stock units to acquire a total of 5,625 shares of the Company’s common stock.
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
12/19/2022
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
-
Arcus Biosciences Announces New Employment Inducement Grants - December 9, 2022
12/9/2022
Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 8,200 shares of the Company’s common stock.
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
11/28/2022
Gilead Sciences, Inc. and Arcus Biosciences announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 24, 2022
11/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company’s common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company’s common stock.
-
Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference
11/14/2022
Arcus Biosciences announced that its management team will participate in a virtual fireside chat at the upcoming 5th Annual Evercore ISI HealthCONx Conference.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 09, 2022
11/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 13,700 shares of the Company’s common stock at an exercise price per share of $24.69, which was the closing price on November 8, 2022, and restricted stock units to acquire a total of 6,850 shares of the Company’s common stock.
-
Arcus Biosciences and its collaboration partner Gilead Sciences announced during Arcus’ third-quarter report that the company had modified its ARC-10 Phase III trial.
-
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
11/2/2022
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers.
-
Arcus Biosciences Announces New Employment Inducement Grants - October 25, 2022
10/25/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 9,100 shares of the Company’s common stock at an exercise price per share of $27.80, which was the closing price on October 24, 2022, and restricted stock units to acquire a total of 4,550 shares of the Company’s common stock.
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
Arcus Biosciences Announces New Employment Inducement Grants - October 11, 2022
10/11/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 35,200 shares of the Company’s common stock at an exercise price per share of $26.15, which was the closing price on October 10, 2022, and restricted stock units to acquire a total of 17,600 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - September 26, 2022
9/26/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 14,700 shares of the Company’s common stock at an exercise price per share of $25.21, which was the closing price on September 23, 2022, and restricted stock units to acquire a total of 7,350 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - September 09, 2022
9/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 33,950 shares of the Company’s common stock at an exercise price per share of $25.70, which was the closing price on September 8, 2022, and restricted stock units to acquire a total of 16,975 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - Aug 24, 2022
8/24/2022
Arcus Biosciences, Inc. announced that, in connection with the appointment of the Company’s new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company’s Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company’s common stock at an exercise price per share of $26.00.
-
Arcus Biosciences to Participate in Two Upcoming Investor Conferences in September 2022
8/24/2022
Arcus Biosciences announced that its management team will participate in the following upcoming investor conferences.
-
Arcus Biosciences Announces New Employment Inducement Grants - Aug 09, 2022
8/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 22,100 shares of the Company’s common stock at an exercise price per share of $27.35, which was the closing price on August 8, 2022, and restricted stock units to acquire a total of 11,050 shares of the Company’s common stock.
-
Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer
8/8/2022
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022.